A Phase 1 interventional study of LX102 subretinal injection in Neovascular Age-Related Macular Degeneration, sponsored by Innostellar Biotherapeutics Co.,Ltd. Active, not recruiting at 3 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Innostellar Biotherapeutics Co.,Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.
Among the 107 studies in Macular Degeneration with a site in China, this one is the 79th largest by enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 20 in phase 1, reaches primary completion later than 4 of the 42 other live ones, and was the 74th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 50–85
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 16 more countries
Ages 50+
Innostellar Biotherapeutics Co.,Ltd · Sites in China
Ages 50–80
Innovent Biologics Technology Limited (Shanghai R&D Center) · Sites in China
Ages 50+
Peking University People's Hospital · Sites in China
Ages 50+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 36 · Phase 3 22 · Phase 4 5
First in 2008; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 62 across the 91 interventional studies, 300 across the 16 observational. Of the 40 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 107 have an industry lead sponsor. The 10 most frequent:
Innostellar Biotherapeutics Co.,Ltd is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Innostellar Biotherapeutics Co.,Ltd has 3 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Degeneration with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972473Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD | 2027-02-28 |
| NCT07189169Phase 3Smilebiotek Zhuhai LimitedQA108 Phase III Study in Subjects With Intermediate AMD | 2027-03-01 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT07053358Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | 2026-11-23 |
| NCT07409389The Hong Kong Polytechnic UniversityRepeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration | 2026-12-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 107 studies in Macular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
This study will enroll subjects aged ≥ 50 years old to receive a single unilateral subretinal injection of LX102 to evaluate its safety and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose of LX102
Genetic: LX102 subretinal injection
Mid dose of LX102
Genetic: LX102 subretinal injection
High dose of LX102
Genetic: LX102 subretinal injection
LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
Incidence of dose-limiting toxicity (DLT)
Incidence of dose-limiting toxicity (DLT) following LX102 subretinal injection at different doses
Time frame: 4 weeks
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Incidence of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following LX102 subretinal injection
Time frame: 52 weeks
Mean change in BCVA from Baseline
BCVA measured by ETDRS
Time frame: 12 weeks, 36 weeks 52 weeks
Mean change in Central Subfield Thickness (CST) from Baseline
CST measured by spectral domain optical coherence tomography (SD-OCT)
Time frame: 12 weeks, 36 weeks 52 weeks
Mean time from LX102 administration to anti-VEGF rescue injection for the first time
Time frame: 52 weeks
Percentage of participants requiring anti-VEGF rescue injection
Time frame: 52 weeks
Mean number of anti-VEGF rescue injections
Time frame: 52 weeks
Plan to share: No
Ran from Feb 2023 to primary completion in Dec 2024, 21 months.
Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 21 months is above that.
Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innostellar Biotherapeutics Co.,Ltd